Antibacterial resistance in companion animals and potential risk to - - PowerPoint PPT Presentation
Antibacterial resistance in companion animals and potential risk to human health risk to human health Professor Susan Dawson f S University of Liverpool y p C Companion animals l Pets in households half of households Dogs
Pets in households – half of households
Dogs 8-10 million dogs Cats – 8-10 million cats Other pets
Horses – 3.5 million people have been
Direct contact with people Direct contact with people
POM-V Treatment of and prophylaxis for bacterial
Prescribed by vets
Adminstered by vets, owners, stable
Compliance
Veterinary surgeons must prescribe and
If no medicine is authorised can then use
A vet medicine authorised in UK for another
Or if not a medicine authorised for human use in UK
O i t d f th b St t
Or imported from another member State
Completion of a prescription log over 5
2 5 .9 % of dogs seen by vets were
Penicillins (esp. amoxicillin/ clavulanic Penicillins (esp. amoxicillin/ clavulanic
Fluoroquinolones – 5 6% of antibacterial Fluoroquinolones
No prescriptions for carbapenems
Most commonly used for wounds,
16% prescriptions for prophylaxis 3 3% of prescriptions were for products 3.3% of prescriptions were for products
1 7 % of horses attended by vets were
34.4% potentiated sulphonam ides 23.5% penicillins 14.3% aminoglycosides 5.1% fluoroquinolones 3.1% 3rd and 4th gen cephalosporins
3 8 % of prescriptions were for products
74% of horse vets reported that they were
Information gained from cpd events, Information gained from cpd events,
Dogs in the community 2 9 % of dogs carried at least one AMR
2 4 % dogs had isolates resistant to 2 4 % dogs had isolates resistant to
20% to tetracycline 20% to tetracycline 17% to trimethoprim
1 5 % of dogs had multidrug resistant
Only one ESBL
4 5 % of faecal samples had AR E.coli Ampicillin 37%
Tetracycline 30% Trimethoprim 24% Trimethoprim 24% Ciprofloxacin 5% 1 8 % samples had multidrug resistant
4 .1 % ESBL
4 hunt kennels; 110 faecal samples Ampicillin resistant E.coli found in 1 0 0 %
Over 8 0 % multidrug resistant Over 8 0 % multidrug resistant No ESBL producing E.coli identified Use of antibacterials was reported to be Use of antibacterials was reported to be
7 2 % samples positive for any resistance 56% trimethoprim
51% tetracycline 46% ampicillin 46% ampicillin 5.4% ciprofloxacin 3 8 % multidrug resistance 6.3% ESBL resistance
103 horses; 457 faecal samples Samples collected within 48 hours of
2 9 % samples positive for ESBL producing 2 9 % samples positive for ESBL producing
Prevalence of resistance lower at Prevalence of resistance lower at
PFGE suggested transmission between
Majority carried bla CTX-M-1 Also carried bla CTX-M-14, bla CTX-M-9, bla CTX-M-20,
Median duration of shedding 22 days Median duration of shedding 22 days
Healthcare associated MRSA – HA-MRSA Community associated MRSA – CA-MRSA
Livestock associated MRSA – LA-MRSA
Dogs attending vets (consultation only)
724 dogs
MRSA 1% MSSA 6.5% MSSA 6.5% MR-CNS 5.5% S.pseudintermedius 11% (none MR) S.pseudintermedius 11% (none MR)
Horses attended by vets (not
678 horses MRSA 0 6% MRSA 0.6% MRS 29% 78% of isolates were multidrug
High level of contact Low levels of MRSA carriage; transmission
Transmission of MRSA from humans to Transmission of MRSA from humans to
High prevalence of E coli carrying AR High prevalence of E.coli carrying AR
Maintain efficacy in animals Maintain efficacy in people
Develop new drugs Maintain our ability as vets to prescribe Maintain our ability as vets to prescribe Ensure infection control with other
Nicola Williams Tom Maddox Amy Wedley Pete Clegg Pete Clegg Gina Pinchbeck Tim Nuttall Defra Bransby Home of